Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Current Assets (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Current Assets readings, the most recent being $26.9 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 3.42% to $26.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.9 million, a 3.42% increase, with the full-year FY2025 number at $26.9 million, up 3.42% from a year prior.
  • Current Assets hit $26.9 million in Q4 2025 for Sunshine Biopharma, down from $28.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $42.0 million in Q2 2022 to a low of $1.8 million in Q2 2021.
  • Median Current Assets over the past 5 years was $25.9 million (2024), compared with a mean of $22.3 million.
  • Biggest five-year swings in Current Assets: soared 5313.51% in 2021 and later plummeted 37.84% in 2023.
  • Sunshine Biopharma's Current Assets stood at $2.2 million in 2021, then surged by 1143.83% to $27.3 million in 2022, then dropped by 8.87% to $24.9 million in 2023, then grew by 4.32% to $26.0 million in 2024, then increased by 3.42% to $26.9 million in 2025.
  • The last three reported values for Current Assets were $26.9 million (Q4 2025), $28.0 million (Q3 2025), and $27.9 million (Q2 2025) per Business Quant data.